Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities
Authors:
- Michael J. PugiaMPMichael J. Pugia
- Meeta PradhanMPMeeta Pradhan
- Rong QiRQRong Qi
- Doreen L. EastesDEDoreen L. Eastes
- Anna GeisingerAGAnna Geisinger
- Bradley J. MillsBMBradley J. Mills
- Zane BairdZBZane Baird
- Aruna WijeratneAWAruna Wijeratne
- Scott M. McAhrenSMScott M. McAhren
- Amber L. MosleyAMAmber L. Mosley
- Anantha ShekharASAnantha Shekhar
- Daniel H. RobertsonDRDaniel H. Robertson
Preprint
Abstract
BACKGROUND: Diabetes is a complex, multi-symptomatic disease that drives healthcare costs through its complications as the prevalence of this disease grows rapidly world-wide. Real-world electronic health records (EHRs) coupled with patient biospecimens, biological understanding, and technologies can lead to identification of new diagnostic markers. METHODS: We analyzed the 20-year EHRs of 1862 participants with midpoint samples (10-year) in an observational study of type 2 diabetes and cardiovascular arterial disease (CVAD) conducted by the Fairbanks Institute to test the diagnostic biomarkers. Participants were assigned to four cohorts (healthy, diabetes, CVAD, CVAD+diabetes) based on EHR data analysis. The immunoassay reference range for circulating autoantibodies against the C-terminal fragment of adiponectin receptor 1 (IgG-CTF) was determined and used to predict outcomes post-sample. RESULTS: The IgG-CTF reference range was determined [75–821 ng/mL] and out-of-range values of IgG-CTF values predicted increased likelihood of additional comorbidities and mortality determined from the EHRs 10 years after sample collection. The probability of mortality was lower in patients with elevated IgG-CTF >821 ng/mL [OR 0.49–0.0] and higher in patients with lowered IgG-CTF <75 ng/mL [OR 3.74–9.64]. Although many patients at the time of sample collection had other conditions (hypertension, hyperlipidemia, or elevated uristatin values), only hypertension correlated with increased likelihood of mortality (OR 4.36–5.34). CONCLUSIONS: This study confirms that retrospective analysis of biorepositories coupled with EHRs can provide insight into novel diagnostic markers and the IgG-CTF marker can predict the likelihood of progressing to additional comorbidities or mortality.Keywords
This publication has 42 references indexed in Scilit:
- Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressureDiabetic Medicine, 2018
- Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health StudyJournal of the American Geriatrics Society, 2018
- Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesThe Lancet, 2014
- Insulin Resistance: Metabolic Mechanisms and Consequences in the HeartArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Tissue–Specific Insulin Signaling, Metabolic Syndrome, and Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- The global burden of diabetes and its complications: an emerging pandemicEuropean Journal of Preventive Cardiology, 2010
- Cardiovascular Disease in Type 2 Diabetes From Population to Man to MechanismsDiabetes Care, 2010
- Role of changes in cardiac metabolism in development of diabetic cardiomyopathyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005